Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
In recent years, diffuse large B-cell lymphoma (DLBCL) has been classified by DNA microarray analysis into the germinal center B-cell-like (GC) type, the activated B-cell-like (ABC) type and type 3. The latter two types can be collectively categorized as the non-GC (NGC) type. From the prognostic perspective, the GC type has a favorable clinical outcome when compared with the NGC type. The protein Fas induces apoptosis of lymphocytes by binding with the Fas ligand (FasL), and escape from such apoptosis is considered to lead to malignant transformation of the cells and unrestricted growth of lymphoma. We proposed a hypothesis that Fas/FasL expression could be possibly related with a better survival of GC type DLBCL and evaluated 69 DLBCL cases immunohistochemically with CD10, Bcl-6, MUM1, Fas and FasL. These lymphomas were classified as GC type (positive for CD10 or Bcl-6 and negative for MUM1) or NGC type. The GC type had a better overall survival rate than the NGC type (P = 0.0723). Among markers as given above, positive CD10 was the most significant prognostic factor for overall survival in total DLBCL (P < 0.05). In the GC type, Fas and FasL expressions were significantly associated with a favorable overall survival (Fas: P < 0.005; FasL: P < 0.05). Hence, Fas or FasL expression might contribute to a better prognosis of this type of DLBCL.
Kojima
Yasushi
Y
First Department of Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
Tsurumi
Hisashi
H
Goto
Naoe
N
Shimizu
Masahito
M
Kasahara
Senji
S
Yamada
Toshiki
T
Kanemura
Nobuhiro
N
Hara
Takeshi
T
Sawada
Michio
M
Saio
Masanao
M
Yamada
Tetsuya
T
Takahashi
Takeshi
T
Tomita
Eiichi
E
Takami
Tsuyoshi
T
Moriwaki
Hisataka
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D017209:Apoptosis / Q000502:physiology; D001402:B-Lymphocytes / Q000378:metabolism / Q000473:pathology; D014408:Biomarkers, Tumor / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage; D004268:DNA-Binding Proteins / Q000032:analysis; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D054278:Embryonal Carcinoma Stem Cells; D053222:Fas Ligand Protein; D005260:Female; D005500:Follow-Up Studies; D018858:Germinal Center / Q000473:pathology; D006801:Humans; D050835:Interferon Regulatory Factors / Q000032:analysis; D007770:L-Lactate Dehydrogenase / Q000097:blood; D015993:Life Tables; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis* / Q000235:genetics; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000473:pathology; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D016016:Proportional Hazards Models; D051560:Proto-Oncogene Proteins c-bcl-6; D016019:Survival Analysis; D016896:Treatment Outcome; D048069:Tumor Necrosis Factors / Q000096:biosynthesis* / Q000235:genetics; D014750:Vincristine / Q000008:administration & dosage; D019014:fas Receptor / Q000096:biosynthesis* / Q000235:genetics; D000099218:Interferon Regulatory Factor-4
D014408:Biomarkers, Tumor; D003520:Cyclophosphamide; D004268:DNA-Binding Proteins; D004317:Doxorubicin; D053222:Fas Ligand Protein; D050835:Interferon Regulatory Factors; D007770:L-Lactate Dehydrogenase; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D011239:Prednisolone; D051560:Proto-Oncogene Proteins c-bcl-6; D048069:Tumor Necrosis Factors; D014750:Vincristine; D019014:fas Receptor; D000099218:Interferon Regulatory Factor-4; C084103:BCL6 protein, human; C505661:FASLG protein, human